Drug-Device Combo Looks Promising for Chronic Sinusitis
OPN-375 is currently marketed under the brand name Xhance for the treatment of nasal polyps in patients 18 years of age and older.
OPN-375 is currently marketed under the brand name Xhance for the treatment of nasal polyps in patients 18 years of age and older.
Healthy late-preterm and term infants who receive a single injection of nirsevimab administered before the RSV season are protected from medically attended RSV-associated lower respiratory tract infection.
Survival of PICU hospitalization for respiratory failure is associated with a reduction in IQ scores relative to matched biological siblings.
How do substance abuse and depression affect the risk for premature mortality in patients with common chronic respiratory and other conditions?
How does T-cell activation evolve following acute COVID-19 infection in patients with long-haul respiratory symptoms?
Inhalation doses for the treatment of asthma and prevention of exercise induced bronchospasm (EIB).
Symptoms comparison of common upper respiratory disorders including the common cold, influenza, pharyngitis, allergic rhinitis, and the novel COVID-19.
A recent survey of patients with aspirin-exacerbated respiratory disease identified trends in patients’ medication use and treatment experience.
BI 1015550 is an investigational oral phosphodiesterase 4B inhibitor with combined antifibrotic and anti-inflammatory effects.